📊 INBX Key Takeaways
Is INBX a Good Investment? Thesis Analysis
Inhibrx is a pre-revenue stage biotech burning $129.8M annually against only $1.3M in revenue, providing approximately 12 months of cash runway before requiring dilutive capital raises. The debt-to-equity ratio of 12.58x combined with a razor-thin equity base of $8M creates unsustainable financial leverage. Deteriorating net losses expanding 108.3% YoY signal worsening operational efficiency.
Why Buy INBX? Key Strengths
- Maintains $124.2M in cash reserves providing near-term liquidity cushion
- Strong current ratio of 3.93x demonstrates adequate working capital management
- Revenue growing 550% YoY shows early commercial traction from base
INBX Investment Risks to Consider
- Unsustainable operating cash burn of $129.8M annually with ~12 months of runway remaining
- Extreme financial leverage with debt-to-equity ratio of 12.58x and minimal $8M equity buffer
- Net losses deteriorating 108.3% YoY with no established path to profitability
Key Metrics to Watch
- Monthly cash burn rate and exact timeline to cash depletion
- Revenue ramp trajectory and progress toward positive unit economics
- Timing and terms of required capital raise and shareholder dilution impact
INBX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.93x current ratio provides a solid financial cushion.
INBX Profitability Ratios
INBX vs Healthcare Sector
How Inhibrx Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INBX Overvalued or Undervalued?
Based on fundamental analysis, Inhibrx Biosciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INBX Balance Sheet & Liquidity
INBX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Inhibrx Biosciences, Inc.'s revenue has declined by 28% over the 5-year period, indicating business contraction. The most recent EPS of $112.62 reflects profitable operations.
INBX Growth Metrics (YoY)
INBX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$28.7M | $-2.28 |
| Q2 2025 | $100.0K | -$28.7M | $-1.85 |
| Q1 2025 | N/A | -$43.3M | $-2.80 |
| Q3 2024 | N/A | -$43.9M | $-2.84 |
| Q2 2024 | $30.0K | -$47.1M | $-4.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INBX Capital Allocation
INBX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Inhibrx Biosciences, Inc. (CIK: 0002007919)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INBX
What is the AI rating for INBX?
Inhibrx Biosciences, Inc. (INBX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INBX's key strengths?
Claude: Maintains $124.2M in cash reserves providing near-term liquidity cushion. Strong current ratio of 3.93x demonstrates adequate working capital management.
What are the risks of investing in INBX?
Claude: Unsustainable operating cash burn of $129.8M annually with ~12 months of runway remaining. Extreme financial leverage with debt-to-equity ratio of 12.58x and minimal $8M equity buffer.
What is INBX's revenue and growth?
Inhibrx Biosciences, Inc. reported revenue of $1.3M.
Does INBX pay dividends?
Inhibrx Biosciences, Inc. does not currently pay dividends.
Where can I find INBX SEC filings?
Official SEC filings for Inhibrx Biosciences, Inc. (CIK: 0002007919) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INBX's EPS?
Inhibrx Biosciences, Inc. has a diluted EPS of $-9.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INBX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inhibrx Biosciences, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INBX stock overvalued or undervalued?
Valuation metrics for INBX: ROE of -1,752.2% (sector avg: 15%), net margin of -10,773.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INBX stock in 2026?
Our dual AI analysis gives Inhibrx Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INBX's free cash flow?
Inhibrx Biosciences, Inc.'s operating cash flow is $-129.8M, with capital expenditures of $31.0K. FCF margin is -9,986.5%.
How does INBX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,773.5% (avg: 12%), ROE -1,752.2% (avg: 15%), current ratio 3.93 (avg: 2).